La Jolla Pharmaceutical Company (OQ:LJPC)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4550 Towne Centre Ct
SAN DIEGO CA 92121-1900
Tel: N/A
Website: www.ljpc.com
IR: See website
<
Key People
Kevin C. Tang
Chairman of the Board
George F. Tidmarsh
President, Chief Executive Officer, Secretary, Director
Dennis M. Mulroy
Chief Financial Officer
Jennifer A. Carver
Chief Operating Officer
James M. Rolke
Chief Scientific Officer
Lakhmir S. Chawla
Chief Medical Officer
Business Overview
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
Financial Overview
For the nine months ended 30 September 2018, La Jolla Pharmaceutical Company revenues increased from $0K to $5.9M. Net loss increased from $76.3M to $154.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - other increase from $11.9M to $25.8M (expense), Stock-based Compensation in R&D increase from $8.1M to $17M (expense).
Employees: 130 as of Dec 31, 2017
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $5.87M as of Sep 30, 2018
EBITDA (TTM): -$185.86M as of Sep 30, 2018
Net annual income (TTM): -$192.60M as of Sep 30, 2018
Free cash flow (TTM): -$152.65M as of Sep 30, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 26,233,631 as of Oct 19, 2018
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization